Citigroup Lowers Zimmer Biomet (ZBH) Price Target to $121.00
Zimmer Biomet (NYSE:ZBH) had its target price lowered by Citigroup from $132.00 to $121.00 in a report issued on Tuesday. The firm currently has a neutral rating on the medical equipment provider’s stock.
Other analysts have also recently issued research reports about the stock. Morgan Stanley raised their target price on shares of Zimmer Biomet from $140.00 to $150.00 in a research note on Monday, January 29th. Deutsche Bank upgraded shares of Zimmer Biomet from a hold rating to a buy rating and set a $128.00 target price for the company in a research note on Tuesday, November 14th. Edward Jones upgraded shares of Zimmer Biomet from a hold rating to a buy rating in a research note on Thursday, November 9th. Jefferies Group restated a buy rating and issued a $136.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Finally, SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a buy rating in a research note on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $141.06.
Shares of Zimmer Biomet (NYSE ZBH) opened at $117.05 on Tuesday. The firm has a market cap of $23,700.00, a price-to-earnings ratio of 13.15, a P/E/G ratio of 2.04 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet has a 52 week low of $108.03 and a 52 week high of $133.49.
In other Zimmer Biomet news, insider Bryan C. Hanson bought 25,077 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.
Large investors have recently bought and sold shares of the business. Bank of Nova Scotia Trust Co. purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $112,000. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $117,000. Cerebellum GP LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $133,000. We Are One Seven LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $137,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $140,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/citigroup-lowers-zimmer-biomet-zbh-price-target-to-121-00/1903560.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.